The Association between IgG and Disease Severity Parameters in CF Patients
Abstract
:1. Introduction
2. Materials and Methods
- Demographics: age, gender
- Weight, height, BMI (at the date of study visit)
- Disease characteristics: pancreatic insufficiency/sufficiency (PI/PS); F508del mutation; CF related diabetes (CFRD); CF liver disease; gastrostomy status; allergic bronchopulmonary aspergillosis (ABPA)
- Sputum cultures: chronic colonization with PA
- Inflammatory markers: IgG and c-reactive protein (CRP) (at the study visit or within three months). Values of IgG were analyzed according to age reference values [13]
- Spirometry results—FVC, FEV1 and FEF 25-75. Reference values were retrieved from Polgar and Quanjer [14]
- LCI—retrieved from multiple breath washout (MBW) measurements, Easy-One Pro, MBW Module (NDD Medical Technologies, Zurich, Switzerland). LCI is defined by the number of functional residual capacity (FRC) turnovers required to washout the nitrogen; thus, elevated LCI (>7) reflects inhomogeneous ventilation [9,15]
- Days of antibiotic treatment for pulmonary exacerbations in the year preceding the study visit (oral (PO), intravenous (IV) and total). Chronic antibiotic therapy, such as azithromycin or treatment for atypical mycobacterium, was not considered to be antibiotic treatment
- Standardized severity score was calculated for each patient at the study visit by the modified Shwachman–Kulczycki (SK). The modified score includes three categories: nutritional status, physical findings, and general activity. Each category is given 5 to 25 points, giving a maximum score of 75 points. A higher score indicates better health [16]
- CT scans were anonymized and a modified Bhalla score was performed by a pediatric radiologist. The score includes the extent of bronchiectasis and number of segments involved, peri-bronchial thickening, mucus plugs, sacculation, bullae, collapse, consolidation, and emphysema. The total score ranges from 0 to 25, with a higher score indicating more severe changes [17].
Statistical Methods
Statistical Analysis Was Performed Using SPSS Version 25
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Elborn, J.S. Cystic fibrosis. Lancet 2016, 388, 2519–2531. [Google Scholar] [CrossRef]
- Muhlebach, M.S.; Clancy, J.P.; Heltshe, S.L.; Ziady, A.; Kelley, T.; Accurso, F.; Pilewski, J.; Mayer-Hamblett, N.; Joseloff, E.; Sagel, S.D. Biomarkers for cystic fibrosis drug development. J. Cyst. Fibros. 2016, 15, 714–723. [Google Scholar] [CrossRef] [Green Version]
- Van de Weert-van, P.B.; Hulzebos, H.J.; Werkman, M.S.; Michel, S.; Vijftigschild, L.A.; van Meegen, M.A.; van der Ent, C.K.; Beekman, J.M.; Arets, H.G. Chronic inflammation and infection associate with a lower exercise training response in cystic fibrosis adolescents. Respir. Med. 2014, 108, 445–452. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Van de Weert-van Leeuwen, P.B.; Slieker, M.G.; Hulzebos, H.J.; Kruitwagen, C.L.J.J.; Van der Ent, C.K.; Arets, H.G.M. Chronic infection and inflammation affect exercise capacity in cystic fibrosis. Eur. Respir. J. 2012, 39, 893–898. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aschermann, S.; Lux, A.; Baerenwaldt, A.; Biburger, M.; Nimmerjahn, F. The other side of immunoglobulin G: Suppressor of inflammation. Clin. Exp. Immunol. 2010, 160, 161–167. [Google Scholar] [CrossRef]
- Moss, R.B. Hypergammaglobulinemia in cystic fibrosis: Role of Pseudomonas endobronchial infection. Chest 1987, 91, 522–526. [Google Scholar] [CrossRef]
- Clerc, A.; Reynaud, Q.; Durupt, S.; Chapuis-Cellier, C.; Nové-Josserand, R.; Durieu, I.; Lega, J.C. Elevated IgG4 serum levels in patients with cystic fibrosis. PLoS ONE 2017, 12, e0181888. [Google Scholar] [CrossRef] [Green Version]
- Kronborg, G.; Pressler, T.; Fomsgaard, A.; Koch, C.; Høiby, N. Specific IgG2 antibodies toPseudomonas aeruginosa lipid A and lipopolysaccharide are early markers of chronic infection in patients with cystic fibrosis. Infection 1993, 21, 297–302. [Google Scholar] [CrossRef] [PubMed]
- Fuchs, S.I.; Eder, J.; Ellemunter, H.; Gappa, M. Lung clearance index: Normal values, repeatability, and reproducibility in healthy children and adolescents. Pediatr. Pulmonol. 2009, 44, 1180–1185. [Google Scholar] [CrossRef] [PubMed]
- Fuchs, S.I.; Sturz, J.; Junge, S.; Ballmann, M.; Gappa, M. A novel sidestream ultrasonic flow sensor for multiple breath washout in children. Pediatr. Pulmonol. 2008, 43, 731–738. [Google Scholar] [CrossRef]
- Subbarao, P.; Milla, C.; Aurora, P.; Davies, J.C.; Davis, S.D.; Hall, G.L.; Heltshe, S.; Latzin, P.; Lindblad, A.; Pittman, J.E.; et al. Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. Ann. Am. Thorac. Soc. 2015, 12, 932–939. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kent, L.; Reix, P.; Innes, J.A.; Zielen, S.; Le Bourgeois, M.; Braggion, C.; Lever, S.; Arets, H.G.M.; Brownlee, K.; Bradley, J.M.; et al. Lung clearance index: Evidence for use in clinical trials in cystic fibrosis. J. Cyst. Fibros. 2014, 13, 123–138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rakesh Vadde Immunoglobulins: Reference Range, Interpretation, Collection and Panels. Available online: https://emedicine.medscape.com/article/2157901-overview (accessed on 13 April 2020).
- Quanjer, P.H.; Borsboom, G.J.J.M.; Brunekreef, B.; Zach, M.; Forche, G.; Cotes, J.E.; Sanchis, J.; Paoletti, P. Spirometric reference values for white European children and adolescents: Polgar revisited. Pediatr. Pulmonol. 1995, 19, 135–142. [Google Scholar] [CrossRef]
- Robinson, P.D.; Latzin, P.; Verbanck, S.; Hall, G.L.; Horsley, A.; Gappa, M.; Thamrin, C.; Arets, H.G.; Aurora, P.; Fuchs, S.I.; et al. Consensus statement for inert gas washout measurement using multiple-and single-breath tests. Eur. Respir. J. 2013, 41, 507–522. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shwachman, H.; Kulczycki, L.L. Long-Term Study of One Hundred Five Patients with Cystic Fibrosis: Studies Made Over a Five- to Fourteen-Year Period. AMA J. Dis. Child. 1958, 96, 6–15. [Google Scholar] [CrossRef]
- Bhalla, M.; Turcios, N.; Aponte, V.; Jenkins, M.; Leitman, B.S.; McCauley, D.I.; Naidich, D.P. Cystic fibrosis: Scoring system with thin-section CT. Radiology 1991, 179, 783–788. [Google Scholar] [CrossRef]
- Proesmans, M.; Els, C.; Vermeulen, F.; De Boeck, K. Change in IgG and evolution of lung function in children with cystic fibrosis. J. Cyst. Fibros. 2011, 10, 128–131. [Google Scholar] [CrossRef] [Green Version]
- Levy, H.; Kalish, L.A.; Huntington, I.; Weller, N.; Gerard, C.; Silverman, E.K.; Celedón, J.C.; Pier, G.B.; Weiss, S.T. Inflammatory markers of lung disease in adult patients with cystic fibrosis. Pediatr. Pulmonol. 2007, 42, 256–262. [Google Scholar] [CrossRef] [Green Version]
- Matthews, W.J., Jr.; Williams, M.; Oliphint, B.; Geha, R.; Colten, H.R. Hypogammaglobulinemia in Patients with Cystic Fibrosis. N. Engl. J. Med. 1980, 302, 245–249. [Google Scholar] [CrossRef]
- Garside, J.P.; Kerrin, D.P.; Brownlee, K.G.; Gooi, H.C.; Taylor, J.M.; Conway, S.P. Immunoglobulin and IgG subclass levels in a regional pediatric cystic fibrosis clinic. Pediatr. Pulmonol. 2005, 39, 135–140. [Google Scholar] [CrossRef]
- Wheeler, W.B.; Williams, M.; Matthews, W.J.; Colten, H.R. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: A 5-year longitudinal study. J. Pediatr. 1984, 104, 695–699. [Google Scholar] [CrossRef]
- Matouk, E.; Nguyen, D.; Benedetti, A.; Bernier, J.; Gruber, J.; Landry, J.; Rousseau, S.; Ahlgren, H.G.; Lands, L.C.; Wojewodka, G.; et al. C-Reactive Protein in Stable Cystic Fibrosis: An Additional Indicator of Clinical Disease Activity and Risk of Future Pulmonary Exacerbations. J. Pulm. Respir. Med. 2016, 6, 1000375. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Fiorotto, R.; Villani, A.; Kourtidis, A.; Scirpo, R.; Amenduni, M.; Geibel, P.J.; Cadamuro, M.; Spirli, C.; Anastasiadis, P.Z.; Strazzabosco, M. The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity. Hepatology 2016, 64, 2118–2134. [Google Scholar] [CrossRef] [PubMed]
CF (n = 69) | |
---|---|
Age (years) | 20.5 ± 11.6 |
Male (%) | 39 (56.5%) |
PI/PS | 36/33 |
BMI (kg/m2) | 20.8 ± 4.9 |
CT score (n = 55) | 9.5 ± 5.6 |
SK score | 63.12 ± 10.6 |
CFRD | 10 (15%) |
CF liver disease | 18 (26%) |
Gastrostomy | 5 (7%) |
ABPA | 4 (6%) |
Chronic PA | 30 (43.5%) |
Days of oral/IV AB | 14.6 ± 17.0/5.8 ± 9.8 |
FVC (L; % pred) | 2.9 ± 1.2; 83.0 ± 19.0 |
FEV1 (L; % pred) | 2.36 ± 1.08; 76.9 ± 22.2 |
FEF 25-75 (L; % pred) | 2.2 ± 1.4; 65.3 ± 35.5 |
LCI (n = 66) | 10.0 ± 2.9 |
IgG (mg/dL) | 1372.7 ± 506.4 |
CRP * (mg/dL) | 0.34 (0.11–1.43) |
r | p Value | |
---|---|---|
FVC (%) | −0.506 | <0.001 |
FEV1 (%) | −0.527 | <0.001 |
FEF25–75 (%) | −0.503 | <0.001 |
LCI | 0.342 | 0.005 |
CT score (n = 55) | 0.435 | 0.001 |
SK score | −0.613 | <0.001 |
Days of oral AB | 0.244 | 0.049 |
Days of IV AB | 0.321 | 0.009 |
CRP (n = 58) | 0.38 | 0.003 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gur, M.; Ben-David, Y.; Hanna, M.; Ilivitzki, A.; Weichhendler, A.; Bar-Yoseph, R.; Toukan, Y.; Masarweh, K.; Bentur, L. The Association between IgG and Disease Severity Parameters in CF Patients. J. Clin. Med. 2021, 10, 3316. https://doi.org/10.3390/jcm10153316
Gur M, Ben-David Y, Hanna M, Ilivitzki A, Weichhendler A, Bar-Yoseph R, Toukan Y, Masarweh K, Bentur L. The Association between IgG and Disease Severity Parameters in CF Patients. Journal of Clinical Medicine. 2021; 10(15):3316. https://doi.org/10.3390/jcm10153316
Chicago/Turabian StyleGur, Michal, Yael Ben-David, Moneera Hanna, Anat Ilivitzki, Adi Weichhendler, Ronen Bar-Yoseph, Yazeed Toukan, Kamal Masarweh, and Lea Bentur. 2021. "The Association between IgG and Disease Severity Parameters in CF Patients" Journal of Clinical Medicine 10, no. 15: 3316. https://doi.org/10.3390/jcm10153316
APA StyleGur, M., Ben-David, Y., Hanna, M., Ilivitzki, A., Weichhendler, A., Bar-Yoseph, R., Toukan, Y., Masarweh, K., & Bentur, L. (2021). The Association between IgG and Disease Severity Parameters in CF Patients. Journal of Clinical Medicine, 10(15), 3316. https://doi.org/10.3390/jcm10153316